Recent developments in enforcement and compliance illustrate some of the pressures that the COVID-19 pandemic has placed on drug quality assurance, particularly at the US border.
The Quality Lowdown: COVID-19's Pressures On Drug Quality
Demand surges, supply surges and investigator travel restrictions are forcing FDA to adopt less restrictive regulatory approaches during the pandemic.
